Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioLineRx (BLRX) Return on Capital Employed: 2023-2025

Historic Return on Capital Employed for BioLineRx (BLRX) over the last 1 years, with Jun 2025 value amounting to -0.52%.

  • BioLineRx's Return on Capital Employed rose 99.00% to -0.52% in Q2 2025 from the same period last year, while for Jun 2025 it was -0.52%, marking a year-over-year increase of 99.00%. This contributed to the annual value of -0.57% for FY2024, which is N/A change from last year.
  • As of Q2 2025, BioLineRx's Return on Capital Employed stood at -0.52%, which was up 21.42% from -0.66% recorded in Q1 2025.
  • In the past 5 years, BioLineRx's Return on Capital Employed ranged from a high of -0.52% in Q2 2025 and a low of -3.18% during Q4 2023.
  • Moreover, its 3-year median value for Return on Capital Employed was -1.02% (2024), whereas its average is -1.33%.
  • Data for BioLineRx's Return on Capital Employed shows a peak YoY surged of 251bps (in 2024) over the last 5 years.
  • Over the past 3 years, BioLineRx's Return on Capital Employed (Quarterly) stood at -3.18% in 2023, then skyrocketed by 251bps to -0.67% in 2024, then soared by 99bps to -0.52% in 2025.
  • Its Return on Capital Employed was -0.52% in Q2 2025, compared to -0.66% in Q1 2025 and -0.67% in Q4 2024.